Clinical trial NCT00515528: Vaccination Plus Ontak in Patients With Metastatic Melanoma
Official title: Randomized Phase II Study of Multipeptide Vaccination With or Without Regulatory T Cell Depletion Using Ontak in Patients With Metastatic Melanoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Melanoma
Keywords: metastatic melanoma
Lead sponsor: University of Chicago
Sponsor class: OTHER
Collaborators: name: Eisai Inc.
First posted: 2007-08-13
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if an experimental melanoma vaccine can produce an immune response in patients with metastatic melanoma, and if combining this vaccine with the drug Ontak can improve these immune responses. It is also hoped that this will lead to tumor shrinkage.

Detailed description: This is an open-label, randomized phase II, single institution study comparing administration of a 4-peptide melanoma vaccine alone or post-Ontak, in patients with metastatic melanoma.

Treatment:

1. Cohort A: Vaccine alone. Patients will receive immunization with an emulsion of 4 melanoma peptides (250 mcg each)/GM-CSF/Montanide injected intradermally/subcutaneously on day 1. A second vaccination will be given 2 weeks later and a third vaccination 2 weeks after that. Patients will be re-evaluated around week 6 and can continue courses of 3 vaccinations (one every 2 weeks) until disease progression.
2. Cohort B: Ontak plus vaccine. Patients will receive Ontak (18 mcg/kg) intravenously on day -4 for one dose. On day 0, they will receive the first immunization with an emulsion of 4 melanoma peptides (250 mcg each)/GM-CSF/Montanide injected intradermally/subcutaneously. A second vaccination will be given 2 weeks later and a third vaccination 2 weeks after that. Patients will be re-evaluated around week 6 and can continue courses of 3 vaccinations (one every 2 weeks) until disease progression. However, no further Ontak will be given.

Duration: Patients may remain on study until disease progression, unacceptable toxicity, patient choice to withdraw, or physician decision to discontinue therapy (due to intervening illness, poor patient compliance, or other situation that would increase patient risk).

Eligibility criteria: Inclusion Criteria:

* Melanoma with evidence of metastatic disease
* Life expectancy of at least 12 weeks.
* Karnofsky performance status index of greater than or equal to 80%.
* Adequate hematopoietic, renal, and hepatic function, defined as:
* Patient must express HLA-A2
* Tumor biopsy: patient must agree to undergo biopsy of accessible tumor before and after therapy, when feasible, to study tumor cell properties and characteristics of immune cells.
* EKG without evidence of arrhythmia or changes that indicate acute ischemia.
* Pulse oximetry showing oxygen saturation of at least 90% on room air.

Exclusion Criteria:

* Significant cardiovascular disease, or cardiac arrhythmia requiring medical intervention.
* Pregnant or nursing women.
* Biological therapy in the 4 weeks prior to the start of dosing.
* Patients with intrinsic immunosuppression, including seropositivity for HIV antibody.
* Serious concurrent infection, including active tuberculosis, hepatitis B, or hepatitis C.
* Concurrent systemic corticosteroids (except physiologic replacement doses)or other immunosuppressive drugs (eg. cyclosporin A).
* Psychiatric illness that may make compliance to the clinical protocol unmanageable or may compromise the ability of the patient to give informed consent.
* Active or history of autoimmune disease
* Active gastrointestinal bleeding or uncontrolled peptic ulcer disease.
* Presence of untreated brain metastases.

Primary outcomes:
measure: Clinical Response Outcome
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
Study officials:
affiliation: University of Chicago
name: Thomas Gajeweski, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Luke JJ, Zha Y, Matijevich K, Gajewski TF. Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial. J Immunother Cancer. 2016 Jun 21;4:35. doi: 10.1186/s40425-016-0140-2. eCollection 2016.